The North America Nuclear Medicine & Stable Isotopes Market size was valued at USD 3,560 Million in 2025 and is expected to reach USD 9,810 Million by 2035 at a CAGR of 9.7% from 2024 to 2035.
The economic impact of tariffs on "North America Nuclear Medicine & Stable Isotopes Market".
Market Growth Drivers
Rising Prevalence of Chronic Diseases: An increasing burden of chronic diseases, particularly cancer and cardiovascular diseases, in North America is significantly driving the demand for nuclear medicine and stable isotopes. Growing incidences of cancer have led to a surge in the utilization of radioisotopes for early and precise diagnostics, such as PET and SPECT scans. According to Cardinal Health, the use of technetium-99m in imaging increased by 7% in 2023, primarily due to its importance in cardiac imaging. Companies like GE Healthcare and Cardinal Health are expanding their radioisotope production infrastructure to meet the rising clinical demand.
Technological Advancements and Product Launches: Companies are heavily investing in research and development to bring advanced nuclear medicine techniques and new stable isotopes into the market. For example, Curium Pharma introduced new streamlined radiopharmaceutical production systems in early 2024, facilitating quicker, safer, and more cost-effective radiotracer synthesis. These innovations are improving clinical outcomes, efficiency, and accessibility, thereby stimulating further market growth.
Market Trends
Increased Strategic Collaborations: The sector is witnessing strong collaborative activity between pharmaceutical firms, isotope suppliers, and healthcare providers. In February 2024, NorthStar Medical Radioisotopes partnered with Mayo Clinic to develop next-gen molybdenum-99 production technologies, aiming to resolve past supply chain challenges. Such collaborations are fostering innovation, ensuring steady isotope supply, and expanding clinical applications.
Shift Towards Theranostics: There is a notable trend towards theranostics—integrating diagnostic imaging and targeted radionuclide therapy. Lantheus Holdings launched a suite of theranostic products in Q1 2024, combining diagnostic agents with therapy, allowing personalized treatment planning for cancer. This is enhancing patient outcomes and driving interest from both clinicians and investors.
Market Opportunity
Expansion of Cyclotron Facilities: The increasing establishment of cyclotron production facilities enables on-site and regional production of isotopes, addressing supply chain disruptions. For instance, Siemens Healthineers plans to open two new cyclotron centers in Canada by late 2024, allowing quicker, localized isotope distribution.
Emergence of Targeted Alpha Therapy (TAT): The market is witnessing opportunity from the rapid adoption of targeted alpha therapy for treating resistant cancers. Companies like Actinium Pharmaceuticals are investing in alpha emitters for targeted cancer therapeutics, a segment expected to see robust growth over the next decade.
North America Nuclear Medicine & Stable Isotopes Market Revenue (USD Million), 2020-2035
The line chart illustrates steady and robust growth in the market, starting from USD 1,850 Million in 2020 and accelerating through 2025, reaching a projected USD 9,810 Million by 2035. The chart highlights a consistent upward trajectory, with marked growth post-2023, driven by technological advancements, increased collaboration, and higher clinical adoption rates. This growth trajectory signifies strong market optimism and expanding opportunities, particularly from 2028 onwards, where revenue dramatically rises year on year, reflecting an increased demand for both diagnostic and therapeutic nuclear medicine solutions.
North America Nuclear Medicine & Stable Isotopes Market by Region Share (%) - 2025
The 2025 regional share pie chart demonstrates the dominant presence of the United States, holding 78% of market share, followed by Canada at 16%, and Mexico at 5%. The 'Others' category represents 1%. The chart highlights that while the U.S. continues to lead due to advanced healthcare infrastructure and high adoption of nuclear medicine technologies, Canada’s share is expanding, supported by government initiatives and new production facilities. Mexico, though smaller in share, is increasingly active in collaborations and adoption of nuclear medicine solutions.
Recent Developments (Jan 2024 - June 2024)
In March 2024, NorthStar Medical Radioisotopes received FDA approval for scaling production of molybdenum-99 at its Wisconsin facility. This enhancement will address shortages in the U.S. supply chain and support nuclear imaging centers nationwide, securing NorthStar's leadership in the market.
In April 2024, Curium Pharma launched its new Iodine-131 radiopharmaceutical platform, enabling higher precision in targeted radiotherapy. Early clinical results show improved patient outcomes for thyroid cancer, strengthening Curium’s product portfolio and market reach.
In May 2024, Siemens Healthineers announced the opening of a new cyclotron production center in British Columbia, Canada. The facility aims to enhance the local supply of PET radioisotopes, reduce logistic delays, and support new partnerships with regional healthcare providers.
Press Releases